Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Medical Dialogues3h
Bristol Myers Squibb gets European Commission nod for Breyanzi for follicular lymphoma
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...
Yahoo Finance4d
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...
Bristol Myers announces EC approval of Breyanzi
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Bristol Myers Gets Expanded European Approval for Breyanzi
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
DelveInsight Business Research, LLP: BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
Investing.com Australia1d
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Le Lézard1d
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
Aadi Bioscience, Inc.  ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, ...